Associations of plasma brain-derived neurotrophic factor (BDNF) and Val66Met polymorphism (rs6265) with long-term cancer-related cognitive impairment in survivors of breast cancer.

Breast Cancer Research and Treatment
Ning Yi YapAlexandre Chan

Abstract

Brain-derived neurotrophic factor (BDNF) and the BDNF Val66Met polymorphism (rs6265) have been implicated in neurodegenerative conditions. This study aimed to investigate the associations of plasma BDNF and rs6265 with cancer-related cognitive impairment (CRCI) at the end of chemotherapy, and with persistent and delayed CRCI up to 24 months post chemotherapy, among survivors of early-stage breast cancer. A multicenter, longitudinal study involving 174 breast cancer patients was conducted. CRCI was assessed using the FACT-Cog (V3) questionnaire and the CANTAB software. Plasma BDNF levels were quantified using an enzyme-linked immunosorbent assay at serial time points and genotyping was achieved using Sanger sequencing. The associations of BDNF and rs6265 with CRCI were analyzed using logistic regressions. A smaller magnitude of reduction in plasma BDNF between baseline and the end of chemotherapy was correlated with protection from overall subjective CRCI (OR 0.88; 95% CI 0.79-0.99). Furthermore, patients with higher plasma BDNF levels at the end of chemotherapy had lower odds of developing persistent overall subjective CRCI (OR 0.74; 95% CI 0.57-0.97) and persistent CRCI in the functional interference domain (OR 0.62; 95% CI 0....Continue Reading

References

Jul 1, 1996·Neurotoxicology and Teratology·P J Fray, T W Robbins
Jun 3, 2005·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Henry K TengBarbara L Hempstead
Jul 1, 2005·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Zhe-Yu ChenFrancis S Lee
Aug 26, 2006·Breast Cancer Research and Treatment·Lisa M McShaneUNKNOWN Statistics Subcommittee of NCI-EORTC Working Group on Cancer Diagnostics
May 27, 2008·Journal of Geriatric Psychiatry and Neurology·John GunstadLeigh Murray
Sep 10, 2008·Chronobiology International·Armando PiccinniLiliana Dell'Osso
Jun 16, 2009·Neuroscience Research·Volkmar Lessmann, Tanja Brigadski
Jul 14, 2009·Cancer Treatment and Research·Janette Vardy
Jul 30, 2011·Journal of the American Geriatrics Society·Angela L JeffersonRichard N Jones
Jun 5, 2012·Cancer Treatment Reviews·Amanda D HutchinsonCarlene Wilson
Aug 21, 2012·European Journal of Oncology Nursing : the Official Journal of European Oncology Nursing Society·Diane Von AhBrandy L Schneider
Dec 21, 2012·Nature Reviews. Neuroscience·Hyungju Park, Mu-ming Poo
Sep 18, 2013·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Yin Ting CheungAlexandre Chan
Jan 8, 2015·Frontiers in Human Neuroscience·Regina L LeckieKirk I Erickson
Apr 9, 2015·Frontiers in Human Neuroscience·Francesco AngelucciAlberto Costa
Aug 16, 2016·Seminars in Hearing·Daniel L Murman
Dec 8, 2016·Current Opinion in Supportive and Palliative Care·Lisa M Wu, Ali Amidi
May 24, 2018·Neuroscience and Biobehavioral Reviews·Mingmei Li, Karen Caeyenberghs
Jul 30, 2019·JNCI Cancer Spectrum·Kevin T LiouJun J Mao

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.